Trial Profile
An Adaptive Phase I/II Dose Escalation Trial of Stereotactic Body Radiation Therapy in Combination With Radiomodulating Agent GC4419 in Locally Advanced Pancreatic Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 19 Dec 2023
Price :
$35
*
At a glance
- Drugs Avasopasem manganese (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Galera Therapeutics
- 01 Dec 2023 According to Results published in the Lancet Oncology, placebo group was terminated early after failing to meet prespecified efficacy parameters. The avasopasem group (data cutoff date: 28 Jun 2021) satisfied boundaries for both efficacy and toxicity.
- 01 Dec 2023 Results assessing efficacy and toxicity afforded by selective dismutase mimetic avasopasem manganese when combined with ablative SBRT published in the Lancet Oncology
- 06 Jan 2022 Status changed from active, no longer recruiting to completed.